Arrowhead Reports Topline Results From Pivotal Phase 3 PALISADE Study Of Investigational Plozasiran; Says Study Successfully Met Primary Endpoint Of Lowering Triglycerides And Met All Key Secondary Endpoints

Benzinga · 06/03 11:36

Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part of the 2024 Summer Series of R&D Webinars.

Familial chylomicronemia syndrome (FCS) is a severe and ultrarare genetic disease often caused by various monogenic mutations.